In the first 22 months of a mavacamten REMS program, few patients needed a temporary interruption in treatment for LVEF below 50%.

The Feminist Majority Foundation—they were heroic. They collected over 700,000 petitions from people across the United States ...

Cytokinetics , Inc. (NASDAQ:CYTK), with a market capitalization of $5.65 billion, is approaching a pivotal moment in its journey to become a leading player in the cardiovascular therapeutics market.

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Delcath Systems markets Hepzato Kit for the treatment of uveal melanoma with unresectable hepatic metastases. Click here to read my analysis of DCTH stock.

However, Spravato remains restricted under the FDA's REMS program due to its abuse potential. Investors will watch how this regulatory win impacts Johnson & Johnson's pharma segment ahead of earnings.

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Given its potential for abuse and misuse, Spravato will be only available through the FDA's Risk Evaluation and Mitigation Strategy (REMS) Program.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

Anyone with unopened, unused cancer medication can donate the drugs at McLaren Central Michigan, and MyMichigan Medical ...

The drug's safety profile as a monotherapy is ... called the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program. MDD affects an estimated 21 million adults in the U.S., and about ...